Last $2.01 USD
Change Today -0.03 / -1.47%
Volume 44.2K
ECTE On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

echo therapeutics inc (ECTE) Snapshot

Open
$2.01
Previous Close
$2.04
Day High
$2.10
Day Low
$1.99
52 Week High
11/26/13 - $4.91
52 Week Low
05/28/14 - $1.53
Market Cap
24.1M
Average Volume 10 Days
37.8K
EPS TTM
$-1.57
Shares Outstanding
12.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ECHO THERAPEUTICS INC (ECTE)

Related News

No related news articles were found.

echo therapeutics inc (ECTE) Related Businessweek News

No Related Businessweek News Found

echo therapeutics inc (ECTE) Details

Echo Therapeutics, Inc. is engaged in the development of transdermal skin permeation and diagnostic medical devices. It is developing Symphony CGM system (Symphony), a needle-free wireless continuous glucose monitoring system for use in hospital critical care units; and Symphony SkinPrep system, a component of its Symphony for enhanced skin permeation that enables extraction of analytes, such as glucose. The company is also engaged in the development Durhalieve, an AzoneTS formulation of triamcinolone acetonide that has completed Phase III clinical trials for the treatment of corticosteroid-responsive dermatoses. It has a licensing agreement with Ferndale Pharma Group, Inc. to develop, market, sell, and distribute Prelude SkinPrep system for skin preparation prior to the application of topical anesthetics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community; a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell Symphony for continuous glucose monitoring for use by medical facilities and/or individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd. The company was founded in 1989 and is headquartered in Philadelphia, Pennsylvania.

28 Employees
Last Reported Date: 03/28/14
Founded in 1989

echo therapeutics inc (ECTE) Top Compensated Officers

Interim Chief Executive Officer, Chief Compli...
Total Annual Compensation: $220.0K
Compensation as of Fiscal Year 2013.

echo therapeutics inc (ECTE) Key Developments

Echo Therapeutics, Inc. Announces Executive Changes

At its town hall meeting, the stockholders of Echo Therapeutics, Inc. removed the three Directors, Vince Enright, William Grieco, and James Smith. Dr. Michael Goldberg appointed as Chairman of the Board.

Echo Therapeutics Appoints Charles T. Bernhardt as Interim Chief Financial Officer

On July 10, 2014, the board of directors of Echo Therapeutics, Inc. appointed Charles T. Bernhardt to serve as Interim Chief Financial Officer of Echo, effective July 16, 2014. Mr. Bernhardt, age 53, is a Certified Public Accountant who most recently served as Chief Financial Officer and Chief Accounting Officer for publicly traded Hemispherx Biopharma, Inc. from 2009 through 2013, at which an excess of $60 million was raised during his tenure.

Echo Therapeutics, Inc. Appoints Kimberly A. Burke to Serve as Interim Chief Executive Officer

Echo Therapeutics, Inc. appointed Kimberly A. Burke to serve as Interim Chief Executive Officer, effective July 1, 2014 and continuing for the sixty-day period expiring on August 30, 2014 or, if earlier, such date as a candidate is identified and appointed by the Board to serve as Echo's Chief Executive Officer. Ms. Burke will also serve as Echo's principal executive officer. In addition to serving as Interim Chief Executive Officer, Ms. Burke will also continue to serve as the General Counsel and Chief Compliance Officer of Echo. Ms. Burke, 40 years old, was appointed as Echo's General Counsel and Senior Vice President in January 2011, as Chief Compliance Officer in April 2012, and she has served as Echo's Secretary since 2010.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECTE:US $2.01 USD -0.03

ECTE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.97 USD -0.12
Bayer AG €100.95 EUR +0.66
Johnson & Johnson $102.19 USD -0.28
Roche Holding AG SFr.270.30 CHF +3.80
View Industry Companies
 

Industry Analysis

ECTE

Industry Average

Valuation ECTE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,001.7x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 713.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ECHO THERAPEUTICS INC, please visit www.echotx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.